BioMarin Closes $850M Notes Offering to Fund Amicus Acquisition

SEC 8-K Filing Notice

Company: BioMarin Pharmaceutical Inc. (BMRN) Filing Date: 2026-02-12 Accession Number: 0001193125-26-048736

Items Filed

Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Summary

BioMarin Pharmaceutical Inc. announced the closing of a $850 million private placement of 5.500% Senior Notes due 2026. The proceeds, along with borrowings from new senior secured term loan facilities totaling $2.8 billion and cash on hand, are earmarked to finance the pending acquisition of Amicus Therapeutics, Inc. and associated fees. BioMarin also anticipates establishing a $600 million senior secured revolving credit facility in connection with the acquisition. The notes are subject to mandatory redemption if the Amicus acquisition is not completed by December 19, 2026, or upon the occurrence of certain other events.

Key Takeaways

BioMarin completes $850M private placement of Senior Notes.
Proceeds will fund the acquisition of Amicus Therapeutics.
New $2.8B senior secured term loan facilities and a $600M revolving credit facility are also planned.
Notes are subject to mandatory redemption if the acquisition fails.
The Indenture contains covenants limiting BioMarin's financial flexibility.

Analysis

This financing move signals BioMarin's strong commitment to acquiring Amicus Therapeutics. The significant debt financing indicates a belief in the strategic value and potential synergies of the acquisition. Investors should monitor the progress of the Amicus acquisition and BioMarin's ability to manage its increased debt load. Competitors in the rare disease space will be watching closely to see how the combined entity impacts the market landscape. The covenants in the Indenture may restrict BioMarin's ability to pursue other strategic initiatives or return capital to shareholders in the near term.

This post was automatically generated from an SEC 8-K filing.